<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharma Market Asia</title>
	<atom:link href="http://pharmamarket.asia/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmamarket.asia</link>
	<description>Worldwide News for Asian Industries</description>
	<lastBuildDate>Thu, 21 Jun 2018 02:28:33 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=4.9.6</generator>

<image>
	<url>http://pharmamarket.asia/wp-content/uploads/2016/11/apple-icon-180x180-64x64.png</url>
	<title>Pharma Market Asia</title>
	<link>http://pharmamarket.asia</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>New Collaboration with INRA Micalis-MGP will Concentrate on DuPont’s Probiotic Strains and the Understanding of these Microbes’ Mechanism of Action on Human Health</title>
		<link>http://pharmamarket.asia/new-collaboration-inra-micalis-mgp-duponts/</link>
		<comments>http://pharmamarket.asia/new-collaboration-inra-micalis-mgp-duponts/#respond</comments>
		<pubDate>Thu, 21 Jun 2018 02:20:29 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[New Products]]></category>
		<category><![CDATA[DuPont]]></category>
		<category><![CDATA[featured]]></category>
		<category><![CDATA[Probiotics]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=244</guid>
		<description><![CDATA[<p>Building upon the recently announced partnership with TFTAK in March 2018, the DuPont Nutrition &#38; Health Microbiome Venture continues to&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/new-collaboration-inra-micalis-mgp-duponts/">New Collaboration with INRA Micalis-MGP will Concentrate on DuPont’s Probiotic Strains and the Understanding of these Microbes’ Mechanism of Action on Human Health</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/new-collaboration-inra-micalis-mgp-duponts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blood vessel-forming cells involved in aggressive brain tumour</title>
		<link>http://pharmamarket.asia/blood-vessel-forming-cells-involved-in-aggressive-brain-tumour/</link>
		<comments>http://pharmamarket.asia/blood-vessel-forming-cells-involved-in-aggressive-brain-tumour/#respond</comments>
		<pubDate>Wed, 20 Jun 2018 17:53:30 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[featured]]></category>
		<category><![CDATA[Malaysia]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=239</guid>
		<description><![CDATA[<p>Targeting cells involved in blood vessel formation could prevent the growth of the most common type of brain tumour Selangor,&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/blood-vessel-forming-cells-involved-in-aggressive-brain-tumour/">Blood vessel-forming cells involved in aggressive brain tumour</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/blood-vessel-forming-cells-involved-in-aggressive-brain-tumour/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Attendance rise sees CPhI &#038; P-MEC India 2018 move to Indian capital</title>
		<link>http://pharmamarket.asia/attendance-rise-sees-cphi-p-mec-india-2018-move-to-indian-capital/</link>
		<comments>http://pharmamarket.asia/attendance-rise-sees-cphi-p-mec-india-2018-move-to-indian-capital/#respond</comments>
		<pubDate>Mon, 11 Jun 2018 18:49:09 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[CPhI]]></category>
		<category><![CDATA[featured]]></category>
		<category><![CDATA[India]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=236</guid>
		<description><![CDATA[<p>Amsterdam, 11 June 2018:  CPhI &#38; P-MEC India (December 10-14, 2018) – organised by UBM – announces that the 12th edition of Asia’s largest&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/attendance-rise-sees-cphi-p-mec-india-2018-move-to-indian-capital/">Attendance rise sees CPhI &#038; P-MEC India 2018 move to Indian capital</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/attendance-rise-sees-cphi-p-mec-india-2018-move-to-indian-capital/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CPhI South East Asia strengthens ASEAN integration by opening Thailand edition in 2019</title>
		<link>http://pharmamarket.asia/cphi-south-east-asia-strengthens-asean-integration-opening-thailand-edition-2019/</link>
		<comments>http://pharmamarket.asia/cphi-south-east-asia-strengthens-asean-integration-opening-thailand-edition-2019/#respond</comments>
		<pubDate>Fri, 13 Apr 2018 01:16:32 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[contract services]]></category>
		<category><![CDATA[CPhI]]></category>
		<category><![CDATA[Thailand]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=232</guid>
		<description><![CDATA[<p>Contract services and 2017 regulations igniting growth in Thailand’s pharma economy, with the event to annually switch between the two&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/cphi-south-east-asia-strengthens-asean-integration-opening-thailand-edition-2019/">CPhI South East Asia strengthens ASEAN integration by opening Thailand edition in 2019</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/cphi-south-east-asia-strengthens-asean-integration-opening-thailand-edition-2019/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Universal Medical Announced its 2017 Annual Results, Profit before Tax Achieved Remarkable Surge by 30.7%</title>
		<link>http://pharmamarket.asia/universal-medical-announced-2017-annual-results-profit-tax-achieved-remarkable-surge-30-7/</link>
		<comments>http://pharmamarket.asia/universal-medical-announced-2017-annual-results-profit-tax-achieved-remarkable-surge-30-7/#respond</comments>
		<pubDate>Wed, 28 Mar 2018 02:19:11 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[featured]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Hong Kong]]></category>
		<category><![CDATA[hospital]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[medical]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=227</guid>
		<description><![CDATA[<p>HONG KONG &#8211; The board (the &#8220;Board&#8221;) of directors (the &#8220;Directors&#8221;) of Universal Medical Financial &#38; Technical Advisory Services Company&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/universal-medical-announced-2017-annual-results-profit-tax-achieved-remarkable-surge-30-7/">Universal Medical Announced its 2017 Annual Results, Profit before Tax Achieved Remarkable Surge by 30.7%</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/universal-medical-announced-2017-annual-results-profit-tax-achieved-remarkable-surge-30-7/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Singapore Institutes Collaborate with Samsung Medical Center to Improve Treatment of Liver Cancer</title>
		<link>http://pharmamarket.asia/singapore-institutes-collaborate-samsung-medical-center-improve-treatment-liver-cancer/</link>
		<comments>http://pharmamarket.asia/singapore-institutes-collaborate-samsung-medical-center-improve-treatment-liver-cancer/#respond</comments>
		<pubDate>Thu, 14 Dec 2017 14:52:59 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[liver cancer]]></category>
		<category><![CDATA[Samsung]]></category>
		<category><![CDATA[Singapore]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=217</guid>
		<description><![CDATA[<p>&#8211; This collaboration creates the world&#8217;s first clinically reliable and robust patient-specific diagnostic and predictive platform to improve treatment of&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/singapore-institutes-collaborate-samsung-medical-center-improve-treatment-liver-cancer/">Singapore Institutes Collaborate with Samsung Medical Center to Improve Treatment of Liver Cancer</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/singapore-institutes-collaborate-samsung-medical-center-improve-treatment-liver-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>DuPont Establishes Microbiome Venture to Lead Development of New Microbiome Science-Based Solutions</title>
		<link>http://pharmamarket.asia/dupont-establishes-microbiome-venture-lead-development-new-microbiome-science-based-solutions/</link>
		<comments>http://pharmamarket.asia/dupont-establishes-microbiome-venture-lead-development-new-microbiome-science-based-solutions/#respond</comments>
		<pubDate>Fri, 01 Dec 2017 19:53:39 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[Denmark]]></category>
		<category><![CDATA[DuPont]]></category>
		<category><![CDATA[microbiome]]></category>
		<category><![CDATA[partnerships]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=213</guid>
		<description><![CDATA[<p>COPENHAGEN, Denmark &#8211; DuPont Nutrition &#38; Health announces the development of a significant new initiative with the creation of a&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/dupont-establishes-microbiome-venture-lead-development-new-microbiome-science-based-solutions/">DuPont Establishes Microbiome Venture to Lead Development of New Microbiome Science-Based Solutions</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/dupont-establishes-microbiome-venture-lead-development-new-microbiome-science-based-solutions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BIOCAD launches the new manufacturing site in North Africa</title>
		<link>http://pharmamarket.asia/biocad-launches-new-manufacturing-site-north-africa/</link>
		<comments>http://pharmamarket.asia/biocad-launches-new-manufacturing-site-north-africa/#respond</comments>
		<pubDate>Fri, 01 Dec 2017 19:20:18 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[bevacizumab]]></category>
		<category><![CDATA[BIOCAD]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Morocco]]></category>
		<category><![CDATA[rituximab]]></category>
		<category><![CDATA[Russia]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=210</guid>
		<description><![CDATA[<p>Russian biotechnology company BIOCAD and Moroccan pharmaceutical company Sothema Labs announced the launch of medicines derived using the technology provided&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/biocad-launches-new-manufacturing-site-north-africa/">BIOCAD launches the new manufacturing site in North Africa</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/biocad-launches-new-manufacturing-site-north-africa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>DuPont Launches Digestive Health Campaign at CPhI India 2017</title>
		<link>http://pharmamarket.asia/dupont-launches-digestive-health-campaign-cphi-india-2017/</link>
		<comments>http://pharmamarket.asia/dupont-launches-digestive-health-campaign-cphi-india-2017/#respond</comments>
		<pubDate>Wed, 15 Nov 2017 17:21:00 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[New Products]]></category>
		<category><![CDATA[CPhI]]></category>
		<category><![CDATA[DuPont]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Mumbai]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=197</guid>
		<description><![CDATA[<p>Range of Clinically Documented Solutions Will Help Boost Gut Health of Indians MUMBAI, India – Many Indians suffer from a weak&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/dupont-launches-digestive-health-campaign-cphi-india-2017/">DuPont Launches Digestive Health Campaign at CPhI India 2017</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/dupont-launches-digestive-health-campaign-cphi-india-2017/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Poor aggregation will see ADC targets fail or face long delays</title>
		<link>http://pharmamarket.asia/poor-aggregation-will-see-adc-targets-fail-face-long-delays/</link>
		<comments>http://pharmamarket.asia/poor-aggregation-will-see-adc-targets-fail-face-long-delays/#respond</comments>
		<pubDate>Wed, 15 Nov 2017 17:12:45 +0000</pubDate>
		<dc:creator><![CDATA[HussainF]]></dc:creator>
				<category><![CDATA[Press Releases]]></category>
		<category><![CDATA[biotechnology]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://pharmamarket.asia/?p=193</guid>
		<description><![CDATA[<p>Experts at ADC Bio warn of impending problems in the ADC pipeline with millions wasted in development costs Wales: ADC Biotechnology&#8230;</p>
<p>The post <a rel="nofollow" href="http://pharmamarket.asia/poor-aggregation-will-see-adc-targets-fail-face-long-delays/">Poor aggregation will see ADC targets fail or face long delays</a> appeared first on <a rel="nofollow" href="http://pharmamarket.asia">Pharma Market Asia</a>.</p>
]]></description>
		<wfw:commentRss>http://pharmamarket.asia/poor-aggregation-will-see-adc-targets-fail-face-long-delays/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
